S

Stenocare A/S
CSE:STENO

Watchlist Manager
Stenocare A/S
CSE:STENO
Watchlist
Price: 0.401 DKK 4.7%
Market Cap: 15.4m DKK

Relative Value

The Relative Value of one STENO stock under the Base Case scenario is 0.158 DKK. Compared to the current market price of 0.401 DKK, Stenocare A/S is Overvalued by 61%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

STENO Relative Value
Base Case
0.158 DKK
Overvaluation 61%
Relative Value
Price
S
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
70
vs Industry
20
Median 3Y
24.7
Median 5Y
13.3
Industry
2.4
vs History
vs Industry
Median 3Y
-5
Median 5Y
-7.1
Industry
20.9
vs History
vs Industry
Median 3Y
-7.4
Median 5Y
-8
Industry
15.9
vs History
vs Industry
Median 3Y
-10.6
Median 5Y
-11.7
Industry
23.7
vs History
vs Industry
25
Median 3Y
3.8
Median 5Y
3.4
Industry
2
vs History
70
vs Industry
18
Median 3Y
24.8
Median 5Y
12
Industry
2.6
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5
vs History
vs Industry
Median 3Y
-5.2
Median 5Y
-8.1
Industry
12.4
vs History
vs Industry
Median 3Y
-5.2
Median 5Y
-7.1
Industry
15.9
vs History
vs Industry
Median 3Y
-7.4
Median 5Y
-8
Industry
14.2
vs History
vs Industry
Median 3Y
-6.9
Median 5Y
-7.6
Industry
17.6
vs History
85
vs Industry
58
Median 3Y
3.3
Median 5Y
3.5
Industry
1.8

Multiples Across Competitors

STENO Competitors Multiples
Stenocare A/S Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
DK
Stenocare A/S
CSE:STENO
14.3m DKK 6.4 -0.4 -0.8 -0.6
US
Eli Lilly and Co
NYSE:LLY
715.6B USD 14.6 64.4 34.7 37.9
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
366.8B USD 4.1 16.8 12.3 16.1
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.9 19.9 13.1 14.9
CH
Roche Holding AG
SIX:ROG
208.6B CHF 3.4 25.2 9.5 11.1
UK
AstraZeneca PLC
LSE:AZN
161.1B GBP 3.9 27.7 130.6 196.9
CH
Novartis AG
SIX:NOVN
181.3B CHF 4.1 16.9 10 13.4
US
Merck & Co Inc
NYSE:MRK
194.3B USD 3 11.1 8.3 10.1
IE
Endo International PLC
LSE:0Y5F
163.5B USD 70.5 -56 261.3 655.3
US
Pfizer Inc
NYSE:PFE
130.8B USD 2.1 16.6 7.2 10.1
P/E Multiple
Earnings Growth PEG
DK
S
Stenocare A/S
CSE:STENO
Average P/E: 24.8
Negative Multiple: -0.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
64.4
50%
1.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
16.8
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
19.9
18%
1.1
CH
Roche Holding AG
SIX:ROG
25.2
32%
0.8
UK
AstraZeneca PLC
LSE:AZN
27.7
36%
0.8
CH
Novartis AG
SIX:NOVN
16.9
17%
1
US
Merck & Co Inc
NYSE:MRK
11.1
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -56 N/A N/A
US
Pfizer Inc
NYSE:PFE
16.6
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
DK
S
Stenocare A/S
CSE:STENO
Average EV/EBITDA: 433.3
Negative Multiple: -0.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.7
31%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.3
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
13.1
14%
0.9
CH
Roche Holding AG
SIX:ROG
9.5
6%
1.6
UK
AstraZeneca PLC
LSE:AZN
130.6
9%
14.5
CH
Novartis AG
SIX:NOVN
10
5%
2
US
Merck & Co Inc
NYSE:MRK
8.3
9%
0.9
IE
E
Endo International PLC
LSE:0Y5F
261.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.2
2%
3.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
DK
S
Stenocare A/S
CSE:STENO
Average EV/EBIT: 1 866.8
Negative Multiple: -0.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.1
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
14.9
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.1
6%
1.8
UK
AstraZeneca PLC
LSE:AZN
196.9
21%
9.4
CH
Novartis AG
SIX:NOVN
13.4
10%
1.3
US
Merck & Co Inc
NYSE:MRK
10.1
12%
0.8
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.1
10%
1